Literature DB >> 18645523

In vitro characterization of multidrug-resistant HIV-1 isolates from a recently infected patient associated with dual tropism and rapid disease progression.

Hiroshi Mohri1, Martin Markowitz.   

Abstract

OBJECTIVE: Multidrug-resistant (MDR) HIV-1 variants are thought to be less fit than wild-type virus. In 2005, we reported a case of transmitted MDR HIV-1 infection associated with dual tropism and rapid clinical progression. Here we report the in vitro characterization of the virus isolates.
METHODS: Replication characteristics of bulk and clonal isolates from this case (MDR-1) were examined and compared with these of a panel of transmitted MDR and wild-type (WT) viruses (MDR-2 approximately 4, WT-1, 2).
RESULTS: Infectivity and frequency of infectious virion of propagated isolates were high in MDR-1 biological clones (mean titer, 3.5 x 10(5) TCID50/mL; mean frequency of infectious virion, 1/2444) and its bulk isolate (3.2 x 10(6) TCID50/mL; 1/301) as compared with the other biological clones (7.3 x 10(3) TCID50/mL; 1/21,320). Upslope (log10 p24/mL/d) of viral replication in peripheral blood mononuclear cell culture was much higher in MDR-1 clones (1.30 +/- 0.30: mean +/- SD) than those of MDR-2 approximately 4 (0.75 +/- 0.08) or WT-1, WT-2 clones (0.82 +/- 0.03). The bulk isolate and dual-tropic biological clones from MDR-1 depleted CD4+ T cells very rapidly in vitro compared with the other viruses tested.
CONCLUSIONS: These findings support the hypothesis that MDR HIV-1 can effectively evolve and compensate not only to retain high-level replication but also to exhibit virulence associated with rapid disease progression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18645523      PMCID: PMC3725736          DOI: 10.1097/QAI.0b013e31817ecb31

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  47 in total

1.  Human immunodeficiency virus type 1 pathogenesis in SCID-hu mice correlates with syncytium-inducing phenotype and viral replication.

Authors:  D Camerini; H P Su; G Gamez-Torre; M L Johnson; J A Zack; I S Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Replicative capacity of human immunodeficiency virus from patients with varying severity of HIV infection.

Authors:  B Asjö; L Morfeldt-Månson; J Albert; G Biberfeld; A Karlsson; K Lidman; E M Fenyö
Journal:  Lancet       Date:  1986-09-20       Impact factor: 79.321

3.  Mechanisms of gastrointestinal CD4+ T-cell depletion during acute and early human immunodeficiency virus type 1 infection.

Authors:  Saurabh Mehandru; Michael A Poles; Klara Tenner-Racz; Victoria Manuelli; Patrick Jean-Pierre; Peter Lopez; Anita Shet; Andrea Low; Hiroshi Mohri; Daniel Boden; Paul Racz; Martin Markowitz
Journal:  J Virol       Date:  2006-10-25       Impact factor: 5.103

4.  Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.

Authors:  T C Quinn; M J Wawer; N Sewankambo; D Serwadda; C Li; F Wabwire-Mangen; M O Meehan; T Lutalo; R H Gray
Journal:  N Engl J Med       Date:  2000-03-30       Impact factor: 91.245

5.  A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression.

Authors:  M E Quiñones-Mateu; S C Ball; A J Marozsan; V S Torre; J L Albright; G Vanham; G van Der Groen; R L Colebunders; E J Arts
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

6.  Pharmacokinetics and safety of AMD-3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers.

Authors:  C W Hendrix; C Flexner; R T MacFarland; C Giandomenico; E J Fuchs; E Redpath; G Bridger; G W Henson
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

7.  Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study.

Authors:  R H Lyles; A Muñoz; T E Yamashita; H Bazmi; R Detels; C R Rinaldo; J B Margolick; J P Phair; J W Mellors
Journal:  J Infect Dis       Date:  2000-03       Impact factor: 5.226

8.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

10.  Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.

Authors:  Viviana Simon; Neal Padte; Deya Murray; Jeroen Vanderhoeven; Terri Wrin; Neil Parkin; Michele Di Mascio; Martin Markowitz
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

View more
  9 in total

1.  A randomized open-label study of 3- versus 5-drug combination antiretroviral therapy in newly HIV-1-infected individuals.

Authors:  Martin Markowitz; Teresa H Evering; Donald Garmon; Marina Caskey; Melissa La Mar; Kristina Rodriguez; Vincent Sahi; Sarah Palmer; Nicole Prada; Hiroshi Mohri
Journal:  J Acquir Immune Defic Syndr       Date:  2014-06-01       Impact factor: 3.731

2.  Enhancing the ligand efficiency of anti-HIV compounds targeting frameshift-stimulating RNA.

Authors:  Viktoriya S Anokhina; John D McAnany; Jessica H Ciesla; Thomas A Hilimire; Netty Santoso; Hongyu Miao; Benjamin L Miller
Journal:  Bioorg Med Chem       Date:  2019-05-09       Impact factor: 3.641

3.  Viral envelope is a major determinant of enhanced fitness of a multidrug-resistant HIV-1 variant.

Authors:  Hiroshi Mohri; Nicole Prada; Martin Markowitz
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

4.  The virologic and immunologic effects of cyclosporine as an adjunct to antiretroviral therapy in patients treated during acute and early HIV-1 infection.

Authors:  Martin Markowitz; Florin Vaida; C Bradley Hare; Daniel Boden; Hiroshi Mohri; Frederick M Hecht; Robert C Kalayjian; Ann Conrad; Donna Mildvan; Judith Aberg; Christine Hogan; J Michael Kilby; Henry H Balfour; Kim Schafer; Douglas Richman; Susan Little
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

5.  Modulation of the proteome of peripheral blood mononuclear cells from HIV-1-infected patients by drugs of abuse.

Authors:  Jessica L Reynolds; Supriya D Mahajan; Ravikunar Aalinkeel; Bindukumar Nair; Donald E Sykes; Anardi Agosto-Mujica; Chiu Bin Hsiao; Stanley A Schwartz
Journal:  J Clin Immunol       Date:  2009-06-20       Impact factor: 8.317

Review 6.  Clinical significance of HIV-1 coreceptor usage.

Authors:  Hanneke Schuitemaker; Angélique B van 't Wout; Paolo Lusso
Journal:  J Transl Med       Date:  2011-01-27       Impact factor: 5.531

7.  HIV-1 Frameshift RNA-Targeted Triazoles Inhibit Propagation of Replication-Competent and Multi-Drug-Resistant HIV in Human Cells.

Authors:  Thomas A Hilimire; Jeffrey M Chamberlain; Viktoriya Anokhina; Ryan P Bennett; Oliver Swart; Jason R Myers; John M Ashton; Ryan A Stewart; Aaron L Featherston; Kathleen Gates; Eric D Helms; Harold C Smith; Stephen Dewhurst; Benjamin L Miller
Journal:  ACS Chem Biol       Date:  2017-05-05       Impact factor: 5.100

8.  Viral and Cellular Factors Leading to the Loss of CD4 Homeostasis in HIV-1 Viremic Nonprogressors.

Authors:  Marta Colomer-Lluch; Athina Kilpelainen; María Pernas; Ruth Peña; Dan Ouchi; Esther Jimenez-Moyano; Judith Dalmau; Concepción Casado; Cecilio López-Galíndez; Bonaventura Clotet; Javier Martinez-Picado; Julia G Prado
Journal:  J Virol       Date:  2021-10-20       Impact factor: 5.103

9.  Rheumatoid Arthritis Disease Activity Is Determinant for ABCB1 and ABCG2 Drug-Efflux Transporters Function.

Authors:  Yemil Atisha-Fregoso; Guadalupe Lima; Virginia Pascual-Ramos; Miguel Baños-Peláez; Hilda Fragoso-Loyo; Juan Jakez-Ocampo; Irazú Contreras-Yáñez; Luis Llorente
Journal:  PLoS One       Date:  2016-07-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.